DNMT3B and posterior cortical atrophy: The comparison between the samples from drugged or unmedicated PCa patients showed that DNMT3B [9/39 (23.0%) vs. 24/51 (47.1%) (p = 0.034)] and DNMT3A [21/39 (53.9%) vs. 41/51 (80.4%) (p = 0.014)] were upregulated in the treatment group, while DNMT1 expression did not change [25/39 (64.1%) vs. 37/51 (72.5%) (p = 0.530)].